X
[{"orgOrder":0,"company":"BiomX","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery Platform","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"BiomX"},{"orgOrder":0,"company":"GentiBio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$1,900.0 million","upfrontCash":"Undisclosed","newsHeadline":"GentiBio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammatory Bowel Diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"GentiBio"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
GentiBio will apply its engineered regulatory T cell platform in a deal with BMS to develop new engineered Treg therapies to treat inflammatory bowel diseases.
Lead Product(s):
Egineered Treg Cell Therapy
Therapeutic Area: Gastroenterology
Product Name: Undisclosed
Highest Development Status: Discovery Platform
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Bristol Myers Squibb
Deal Size: $1,900.0 million
Upfront Cash: Undisclosed
Deal Type: Collaboration
August 10, 2022
Details:
Under the collaboration BiomX will utilize its XMarker microbiome-based biomarker discovery platform with the goal of identifying biomarkers for a pathogenic bacterium thought to be associated with IBD.
Lead Product(s):
Engineered Phage Therapy
Therapeutic Area: Gastroenterology
Product Name: Undisclosed
Highest Development Status: Discovery Platform
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Boehringer Ingelheim GmbH
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
June 28, 2022